Company Filing History:
Years Active: 2018
Title: Innovations of Shu Shi in Diabetes Treatment
Introduction
Shu Shi is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. His work focuses on addressing critical health issues such as type II diabetes and obesity.
Latest Patents
Shu Shi holds a patent for a long-acting blood sugar decreasing fusion protein. This innovative invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section. The fusion protein exhibits the biological activity of GLP-1 and has a significantly prolonged half-life in vivo. It can be utilized to treat type II diabetes, obesity, and other diseases by decreasing serum glucose, suppressing gastrointestinal motility, and managing food intake.
Career Highlights
Shu Shi is currently employed at Genor Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work has the potential to transform the treatment landscape for patients suffering from metabolic disorders.
Collaborations
Shu Shi collaborates with talented individuals in his field, including Joe Zhou and Qing Zhou, who contribute to the innovative environment at Genor Biopharma Co., Ltd.
Conclusion
Shu Shi's contributions to the field of biotechnology, particularly through his patented fusion protein, highlight his commitment to improving health outcomes for individuals with diabetes and obesity. His work exemplifies the impact of innovation in addressing pressing medical challenges.